TheraPPI Bioscience-novel protein–protein interaction in the RAS–MAPK pathway

TheraPPI Bioscience-novel protein–protein interaction in the RAS–MAPK pathway refers to a lead therapeutic program developed by TheraPPI Bioscience. The program focuses on small molecules that modify a newly discovered protein-protein interaction (PPI) between ERK (Extracellular signal-regulated kinase) and MyD88 (Myeloid differentiation primary response 88). This interaction, discovered by the company's founders and published in *Nature Communications*, is a critical node in the RAS-MAPK pathway, which is hyperactivated in over 40% of human cancers. The lead oncology program utilizes a triple mechanism of action: direct induction of cancer cell death, prevention of acquired resistance (common with BRAF/MEK inhibitors), and activation of an anti-tumoral immune response. It is currently in preclinical development for the treatment of advanced cancers.

Other names

ERK/MyD88 interaction inhibitorTheraPPI lead programERK-MyD88 PPI inhibitorERK-MyD-88 PPI inhibitorERK-MyD 88 PPI inhibitor